Oncology Applications in the US Market
In the United States, oncology practices contribute significantly to erythropoietin drug utilization. Chemotherapy-induced anemia affects a substantial proportion of cancer patients. ESAs help reduce fatigue, enhance treatment tolerance, and limit reliance on blood transfusions.
Oncology guidelines in the US recommend careful patient selection and hemoglobin monitoring. The goal is to balance symptom relief with minimized risk. Multidisciplinary cancer care teams evaluate each patient’s condition before initiating ESA therapy.
Cancer treatment centers, outpatient infusion clinics, and hospital oncology departments are major users of erythropoietin drugs. As cancer incidence rises and therapies become more intensive, supportive care solutions remain essential.